Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Regulation

FDA Actions

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Federal officials moved to curb mass compounding, with a DOJ referral citing safety and misleading marketing concerns.

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

FDA Posts More Than 100 Warning Letters in Drug Ad Crackdown, Targeting Hims, Lilly and Novo